I think that's potential gain. If it was prior to launch, it would be a bigger value swing. After launch though, it's primarily about earnings/scripts. This gives the potential for huge income/scripts, and once approved should quickly increase both. At this point, it gives investors more upside potential / less downside risk.
I lost 80% of my gain in AFFY. Sold almost every Biostock.
I saved AMRN & EXEL... my last bets on Biostocks.
I swear myself not to look more Biostock.... anymore.
Not only you have to dig deep to understand.... compare..... in a field where you can get only a part of it, unless you're a Doc (and I'm not).
With AFFY, I discovered how a Company with a great drug can screw its shareholders as well.
I tell you.... Omontis will sell Billions...... 0.02% in fatal events.... 25k patients.... no sense in what I've seen.... the FDA neither ask for a recall.!!!!
The management (AFFY's) is croock... sold the whole Company's value.
They will meet themselves in a hole.... sooner or later, after the trials.